General
Preferred name
Orforglipron
Synonyms
LY3502970 ()
GLP-1 receptor agonist 1 ()
LY-3502970 ()
Orforglipron hemicalcium ()
ORFORGLIPRON CALCIUM ()
P&D ID
PD102109
CAS
2212020-52-3
Tags
available
drug candidate
Drug Status
investigational
Max Phase
1.0
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Oforglipron (LY3502970) is an oral, nonpeptide glucagon-like peptide-1 receptor (GLP-1R) agonist that was developed as a potential antidiabetic medication . It is a partial agonist (relative to native GLP-1), that biases GLP-1R signalling towards G protein activation and is devoid of β-arrestin recruitment activity.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
6
Cayman Chemical Bioactives
ChEMBL Drugs
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
12
Molecular Weight
882.38
Hydrogen Bond Acceptors
13
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
11
Aromatic Ring Count
8
cLogP
7.44
TPSA
155.93
Fraction CSP3
0.38
Chiral centers
4.0
Largest ring
6.0
QED
0.17
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
member
Pathway
GPCR/G protein
Target
GCGR
Source data
